Miraculins Licenses Preeclampsia Biomarker Panel from Mount Sinai

Aug 07, 2008

NEW YORK (GenomeWeb News) – Diagnostics developer Miraculins has agreed to license a panel of biomarkers from Mount Sinai Hospital that it will use to develop diagnostic assays to detect preecleampsia, the company said today.

These markers have shown evidence that they may help to diagnose the disease in its earliest stages, Winnipeg, Manitoba-based Miraculins said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Main menu